Skip to main content

Yesterday, June 7, 2016, 85 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $15.84 to $78,975,000.00.

Highlighted Stocks Traded by Insiders:

Foundation Medicine (FMI) - FREE Research Report

Daly David, who is Chief Commercial Officer at Foundation Medicine, sold 472 shares at $21.66 on June 7, 2016. Following this transaction, the Chief Commercial Officer owned 114,458 shares meaning that the stake was reduced by 0.41% with the 472-share transaction.

The shares most recently traded at $20.51, down $1.15, or 5.61% since the insider transaction. Historical insider transactions for Foundation Medicine go as follows:

  • 4-Week # shares bought: 9,100
  • 4-Week # shares sold: 480
  • 12-Week # shares bought: 9,100
  • 12-Week # shares sold: 480
  • 24-Week # shares bought: 9,100
  • 24-Week # shares sold: 1,621

The average volume for Foundation Medicine has been 203,600 shares per day over the past 30 days. Foundation Medicine has a market cap of $745.0 million and is part of the health care sector and health services industry. Shares are down 1.71% year-to-date as of the close of trading on Tuesday.

Foundation Medicine, Inc. provides various molecular information products in the United States. Currently, there is 1 analyst who rates Foundation Medicine a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMI - FREE

TheStreet Quant Ratings

rates Foundation Medicine as a

TheStreet Recommends

sell

. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, deteriorating net income and feeble growth in its earnings per share. Get the full

Foundation Medicine Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gentex (GNTX) - FREE Research Report

Bauer Fred, who is Chairman of the Board & CEO at Gentex, sold 266,300 shares at $16.42 on June 7, 2016. Following this transaction, the Chairman of the Board & CEO owned 6.4 million shares meaning that the stake was reduced by 4.02% with the 266,300-share transaction.

The shares most recently traded at $16.41, down $0.01, or 0.04% since the insider transaction. Historical insider transactions for Gentex go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Gentex has been 2.1 million shares per day over the past 30 days. Gentex has a market cap of $4.7 billion and is part of the consumer goods sector and automotive industry. Shares are up 2.75% year-to-date as of the close of trading on Tuesday.

Gentex Corporation designs, develops, manufactures, and markets automatic-dimming rearview mirrors and electronics for the automotive industry; dimmable aircraft windows for the aviation industry; and commercial smoke alarms and signaling devices for the fire protection industry worldwide. The stock currently has a dividend yield of 2.19%. The company has a P/E ratio of 14.8. Currently, there are 4 analysts who rate Gentex a buy, 2 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNTX - FREE

TheStreet Quant Ratings

rates Gentex as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Gentex Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Century Bancorp (CNBKA) - FREE Research Report

Filler James J, who is 10% Owner at Century Bancorp, bought 1,000 shares at $42.55 on June 7, 2016. Following this transaction, the 10% Owner owned 515,307 shares meaning that the stake was boosted by 0.19% with the 1,000-share transaction.

The shares most recently traded at $42.10, down $0.45, or 1.07% since the insider transaction. Historical insider transactions for Century Bancorp go as follows:

  • 4-Week # shares bought: 7,031
  • 12-Week # shares bought: 14,096
  • 24-Week # shares bought: 28,749

The average volume for Century Bancorp has been 3,800 shares per day over the past 30 days. Century Bancorp has a market cap of $236.4 million and is part of the financial sector and banking industry. Shares are down 1.2% year-to-date as of the close of trading on Monday.

Century Bancorp, Inc. operates as a bank holding company for Century Bank and Trust Company that provides banking products and services. It accepts savings accounts, NOW accounts, demand deposits, time deposits, and money market accounts, as well as cash management accounts. The stock currently has a dividend yield of 1.13%. The company has a P/E ratio of 8.4.

Exclusive Offer: Get the latest Stock Analysis on CNBKA - FREE

TheStreet Quant Ratings

rates Century Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Century Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.